SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Esperion Therapeutics, Inc. of Class Action Lawsuit and a L...
January 13 2016 - 2:48PM
The following statement is being issued by Levi & Korsinsky,
LLP:
To: All persons or entities who
purchased or otherwise acquired securities of
Esperion Therapeutics, Inc. (“Esperion”)
(NASDAQ:ESPR) between August 18, 2015 and September 28,
2015.
You are hereby notified that a
securities class action lawsuit has been commenced in the USDC for
the Eastern District of Michigan. To get more information
go to: http://zlk.9nl.com/esperion-espr.
The complaint alleges that Defendants issued
false and misleading statements regarding the Company’s business
and prospects, including that there was no clear path to approval
for ETC-1002, the Company’s lead product candidate designed to
lower LDL-cholesterol levels, and that the FDA had encouraged the
Company to initiate a cardiovascular outcomes trial (“CVOT”) and
that completion of a CVOT could be necessary prior to approval of
ETC-1002.
On August 17, 2015, Esperion reported to
investors material events from an August 2015 meeting with the FDA;
the Company stated that during the meeting it was informed by the
FDA that the Company would not have to complete a CVOT to gain
approval of ETC-1002. Then in a September 28, 2015 news release the
Company noted that the FDA had actually “encouraged the Company to
initiate a cardiovascular outcomes trial promptly” and it may be
necessary to have a completed CVOT prior to approval.
If you suffered a loss in Esperion you
have until March 14, 2016 to request that the Court
appoint you as lead plaintiff. Your ability to share in any
recovery doesn’t require that you serve as a lead plaintiff. To
obtain additional information, contact Joseph E. Levi, Esq. either
via email at jlevi@zlk.com or by telephone at (212) 363-7500,
toll-free: (877) 363-5972, or visit
http://zlk.9nl.com/esperion-espr.
Levi & Korsinsky is a national firm with
offices in New York, New Jersey, California, Connecticut, and
Washington D.C. The firm’s attorneys have extensive expertise and
experience representing investors in securities litigation
involving financial fraud, and have recovered hundreds of millions
of dollars for aggrieved shareholders. Attorney advertising. Prior
results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Eduard Korsinsky, Esq.
30 Broad Street - 24th Floor
New York, NY 10004
Tel: (212) 363-7500
Toll Free: (877) 363-5972
Fax: (212) 363-7171
www.zlk.com
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Esperion Therapeutics (NASDAQ:ESPR)
Historical Stock Chart
From Jul 2023 to Jul 2024